Partnership16 Dec 2025, 03:52 pm
Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib from Hansoh Pharma, Strengthening Oncology Strategy
AI Summary
Glenmark Pharmaceuticals Ltd. has entered into an exclusive license, collaboration, and distribution agreement with Jiangsu Hansoh Pharmaceutical Group Co., Ltd. for Aumolertinib, a third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) for the treatment of non-small cell lung cancer (NSCLC). Glenmark will develop and commercialize Aumolertinib across Middle East and Africa, Southeast & South Asia, Australia, New Zealand, Russia/CIS, and a few selected Caribbean countries. The agreement includes an upfront payment, potential regulatory and commercial milestone payments, and tiered royalties on net sales in the licensed territories.
Key Highlights
- Glenmark secures exclusive multi-regional rights to Aumolertinib, a third-generation EGFR-TKI from Hansoh Pharma.
- Aumolertinib is approved for the treatment of NSCLC with activating EGFR mutations and T790M mutation-positive NSCLC.
- The partnership includes an upfront payment, potential milestone payments, and royalties on net sales in the licensed territories.
- The deal strengthens Glenmark’s oncology strategy across high-potential markets.
- Aumolertinib is a strategic addition to Glenmark’s near-term commercial pipeline and enhances its ability to serve patients with EGFR-mutated lung cancer.